Express News | Gilead : Leerink Partners Raises Target Price to $99 From $96

Breakings14minutes ago

Gilead Sciences' Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating

TipRanks37minutes ago · Ratings

Oppenheimer raised the Target Price of Gilead Sciences to $115.

Gelonghui December 11 | Oppenheimer: Increased the Target Price for Gilead Sciences from $105 to $115, maintaining an "Outperform" rating. (Gelonghui)

Gelonghui Finance16:54 · Ratings

BofA Securities Initiates Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $109

Futu News16:32 · Ratings

BofA Restarts Coverage of 11 Large-cap Biopharmas

Seeking Alpha06:01

Unusual Options Activity: AI, MSTR and Others Attract Market Bets, AI V/OI Ratio Reaches 249.3

EST Dec 10th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options

Futu News05:30